<DOC>
	<DOC>NCT00242294</DOC>
	<brief_summary>The aim of the study is to investigate the effect of roflumilast (APTA-2217) on lung function in patients with chronic obstructive pulmonary disease (COPD). Roflumilast will be administered orally once daily. The study duration consists of a baseline period (4 weeks) and a treatment period (24 weeks). The study will provide further data on safety, tolerability, and effectiveness of roflumilast.</brief_summary>
	<brief_title>Efficacy and Safety of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-06)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Main inclusion criteria: Patients with chronic obstructive pulmonary disease Current smoker or exsmoker 30 to 80% of predicted FEV1 after inhalation of short acting beta stimulant Main exclusion criteria: Patients with poorly controlled COPD Patients who need for longterm oxygen therapy Patients who have concurrent respiratory diseases such as asthma, diffuse panbronchiolitis, congenital sinobronchial syndrome, bronchiolitis obliterans, bronchiectasis, active tuberculosis, pneumoconiosis, pulmonary lymph vascular myoma, which are considered to affect the evaluation</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>Phosphodiesterase 4 inhibitor</keyword>
	<keyword>Roflumilast</keyword>
</DOC>